"This week a report by Vogue Business found that out of the 9,038 looks presented across 198 shows in the womenswear collections earlier this month, 97.1% were shown on straight-size models who measured between a US size 0-4 (the equivalent of a UK 4-8). Only 0.9% of models were plus-size, also known as curve (UK 18+), while 2% were mid-size (UK 10-16)."
"Elektra Kotsoni, the deputy editorial director of Vogue Business, said it was the lowest proportion since her team started compiling the biannual report two and half years ago. She describes the outlook as horrible. Anna Shillinglaw, the founder of the model agency Milk Management, says she isn't surprised. Previously, the body positivity movement was growing with curve models doing the same shows and shoots as straight-sized models. But recently there has been a massive decline. The industry has literally done a 360 turn."
"The widespread use of GLP-1 weight-loss drugs such as Ozempic is a contributing factor, with their use proliferating among celebrities and thinness now being normalised beyond the catwalks. Although GLP-1s were originally developed to treat diabetes, they have quickly been co-opted for weight loss, leading to shortages for patients. In the UK about 1.5 million people are thought to be buying them through private prescriptions. There is also a growing parallel market online."
Out of 9,038 looks across 198 womenswear shows, 97.1% were shown on models measuring US size 0-4. Only 0.9% of models were plus-size and 2% mid-size. In Milan only four of 55 brands cast non-straight-size models, the lowest proportion since such data has been compiled. Industry figures describe the outlook as horrible and note a reversal from recent body positivity gains. The proliferation of GLP-1 weight-loss drugs, resulting shortages, private purchases and parallel online markets are cited as contributing factors, alongside growing demand for body modification procedures.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]